News | January 08, 2026
Lilly to buy Ventyx Biosciences for $1.2 billion
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Subscribe To Our Newsletter & Stay Updated
